

Protocol FOR SWITCHING TO NEWER BASAL INSULINS

FROM:	TO:		
	Insulin Glargine 300 units/mL (Toujeo):	Glargine 100 units/mL (Basaglar):	Degludec (Tresiba)
Insulin glargine 300 units/mL (Toujeo) OD		Reduce by 20%*	Reduce by 20%*
Insulin glargine 100 units/mL (Lantus) OD	Same dose*	Same dose	Same dose**‡
Insulin glargine 100 units/mL (Lantus) BID	Same dose	Same dose BID	Reduce by 20%
Insulin detemir (Levemir) OD	Same dose	Same dose	Same dose‡
Insulin detemir (Levemir) BID	Reduce by 20%	Reduce by 20%	Reduce by 20%
Insulin NPH OD	Same dose	Same dose	Same dose‡
Insulin NPH BID	Reduce by 20%	Reduce by 20%	Reduce by 20%

*A 10–17% higher dose requirement with insulin glargine 300 units/mL vs. 100 units/mL has been observed. Therefore, a higher daily insulin glargine 300 units/mL dose may be needed to achieve target ranges for plasma glucose level.

**A small 3–4% lower dose requirement with insulin degludec vs. insulin glargine 100 units/mL has been observed in the SWITCH

‡For type 1 diabetes: reduce by 20%

TOUJEO™ SoloSTAR® Product Monograph. Sanofi-aventis Canada, Inc. May 2015.
 BASAGLAR™ Product Monograph. Eli Lilly Canada, Inc. September 2015.
 DEGLUDEC™ Product Monograph. Novo Nordisk Canada Inc. August 2017.